Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Semen quality of 4480 young cancer and systemic disease patients: baseline data and clinical considerations.
Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells.
Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study.
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.
Oracle Cladribine in Early Multiple Sclerisis (MS) (ORACLE MS)
Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and RORγt responses and by increasing IL-10 production in experimental allergic encephalomyelitis.
Power estimation for non-standardized multisite studies.
Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies.
One can prevent post-partum MS relapses by exclusive breast feeding: no.
The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
PhIP-Seq characterization of autoantibodies from patients with multiple sclerosis, type 1 diabetes and rheumatoid arthritis.
Interferon in relapsing-remitting multiple sclerosis.
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Results of Phase III BRAVO Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment
Evaluation of pattern-reversal visual evoked potential in patients with neuromyelitis optica.
Refining diagnosis of multiple sclerosis with revised MRI criteria.
Santhera's Phase III program with Catena®/Raxone® in Duchenne muscular dystrophy on track to deliver pivotal data early in 2Q 2014
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
Glatiramer Acetate and Nanny Proteins Restrict Access of the Multiple Sclerosis Autoantigen Myelin Basic Protein to the 26S Proteasome.
Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration.
Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre.
Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease.
RTL therapy for multiple sclerosis: a Phase I clinical study.
New data from ENDORSE show positive results continued over five years with TECFIDERA® (dimethyl fumarate) in a wide range of multiple sclerosis patients

Pages